Outcome of Board Meeting

Ref: MHL/Sec&Legal/2026-27/56 November 03, 2026 BSE Limited National Stock Exchange of India Limited Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Outcome of Board Meeting held on Tuesday, November 03, 2026 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (‘SEBI Listing Regulations’), this is to inform you that the Board of Directors of the Company, at its meeting held Today i.e., Tuesday, November 03, 2026, has, inter alia, considered the following matters: 1. Financial Results Approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026, and noted the limited review report thereon, issued by the Statutory Auditors of the Company. The financial results together with the limited review report are enclosed herewith. The financial results are also being made available on the Company’s website at www.metropolisindia.com. 2. Declaration of Interim Dividend Declared Interim Dividend of INR 1/- (Indian Rupee One only) per equity share of face value of INR 2/- (Indian Rupees Two only) each for the financial year 2026-27. The record date for the purpose of payment of Interim Dividend shall be Monday, November 09, 2026. The Interim Dividend will be paid within 30 days of its declaration. The meeting commenced at 02:15 p.m. (IST) and concluded at 05:50 p.m. (IST). You are requested to take the above information on record. Thanking you, Yours faithfully, For Metropolis Healthcare Limited Kamlesh C Kulkarni Head - Legal & Secretarial Encl: a/a e Chartered Accountants Del oO itte One International Center Tower 3, 27th-32nd Floor ki i | Senapati Bapat Marg (HI a Ss l n Ss &e Se Ss Elphinstone Road (West) Chartered Accountants LLP MMauhmabraais-h4tr0a0, 0I1n3d i Tel: 22 6185 4000 Fax: 22 6185 4101 INDEPENDENT AUDITOR’S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF METROPOLIS HEALTHCARE LIMITED 1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of METROPOLIS HEALTHCARE LIMITED (“the Company”), for the quarter and six months ended September 30, 2026 (“the Statement”), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the Listing Regulations”). 2. This Statement, which is the responsibility of the Company’s Management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulatio3n3 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company’s personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. Regd. Office: 19th floor, Shapath-V, Opp. Karnavati Club, S.G. Highway, Anmedabad-380 015, Gujarat, India. Deloitte Haskins & Sells Chartered Accountants LLP is registered with Limited Liability having LLP identification No: AAX-2454 Deloitte Haskins & Sells Chartered Accountants LLP 5. The standalone financial results of the Company for the quarter ended June 30, 2026, for the quarter and six months ended September 30, 2025 and for the year ended March 31, 2026 included in the Statement, were reviewed / audited by another auditor who expressed an unmodified conclusion / opinion on those statements on August 04, 2026, November 04, 2025 and May 13, 2026, respectively. Our conclusion on the statement is not modified in respect of this matter. For Deloitte Haskins & Sells Chartered Accountants LLP Chartered Accountants (Firm’s Registration No. 117364W/W-100739) Pallavi Sharma Partner Membership No. 113861 UDIN: 26113861XYCPHV3828 Place: Mumbai Date: November 03, 2026 Metropolis Healthcare Limited Registered and Corporate Office: 4th Floor, East Wing, Plot 254 B, Nirlon House, Dr. Annie Besant Road, Worli. Mumbai - 400030, Maharashtra, India CIN:L73 100MH2000PLC 192798 Email: support@metropolisindia.com ; Contact No.: 8422 801 801; Website: www.metropolisindia.com Global Reference Lab: 4th Floor Commercial Bldg. - 1A, Kohinoor Mall, Vidyavihar (West), Mumbai - 400070, Maharashtra, India Statement of unaudited Standalone Financial Results for the quarter and six months ended September 30, 2026 (Rs. in million) Quarter ended Six Months ended Year ended r. No. |Particul September 30, June 30, | September 30,| September 30, | September 30, Sr No.) Particulars 2026 2026 2025 2026 2025 wasnt (Unaudited) | (Unaudited) | (Unaudited) (Unaudited) (Unaudited) (Audited) Continuing operations 1 {Income a) Revenue from operations 4,169.34 3,722.84 3,554.57 7,892.18 6,787.27 13,654.72 b) Other income 89.88 51.86 25.20 141.74 52.99 163.31 Total Income 4,259.22 3,774.70 3,579.77 8,033.92 6,840.25 13,818.03 2 _|Expenses a) Cost of materials consumed 725.16 684.74 682.14 1,409.90 1,295.72 2,527.18 b) Laboratory testing charges 92.13 67.68 40.27 159.81 80.82 180.18 c) Employee benefits expense 840.27 852.43 753.93 1,692.70 1,476.62 2,974.38 d) Finance costs 55.46 47.73 39.66 103.19 82.60 191.87 e) Depreciation and amortisation expense 283.17 278.06 277.88 561.23 556.47 1,161.68 f) Other expenses 1,324.49 1,180.30 1,166.61 2,504.79 2,254.90 4,590.75 Total Expenses 3,320.68 3,110.94 2,960.49 6,431.62 5,747.13 11,626.04 3 {Profit before exceptional items and tax (1) - (2) 938.54 663.76 619.28 1,602.30 1,093.12 2,191.99 4 |Exceptional Items (Refer note 6) - - - - - 79,57 5 |Profit before tax (3) - (4) 938.54 663.76 619.28 1,602.30 1,093.12 2,112.42 6 |Tax expenses Current tax : -for the year: 240.70 168.78 173.53 409.48 305.29 571.86 -tax adjusted for earlier years: - - - - 3.70 3.70 Deferred tax (credit) 10.33 (11.56) (19.15) (1.23) (34.36) (34.55) Total tax expenses 251.03 157.22 154.38 408.25 274.63 541.01 7 )Profit for the period / year from continuing operations (5) - (6) 687.51 506.54 464.90 1,194.05 818.49 1,571.41 8 |Discontinued Operations (Refer note 4) Profit/(Loss) before tax from discontinued operation - (0.95) 1.91 (0.95) 4.89 4.57 Tax expense of discontinued operations - (0.24) 0.48 (0.24) 1.23 1.15 Profit/(Loss) after tax from discontinued operations - (0.71) 1.43 (0.71) 3.66 3.42 9 Profit for the period/year (7) + (8) 687.51 505.83 466.33 1,193.34 822.1 [Showing first 8,000 characters — download PDF for full document]